Skip to content

Study · Randomized controlled trial · 2026

3 results

Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials.

Sattar N, Srinath R, García-Pérez LE, Lee CJ, Karanikas CA, Chen X, Plat A

PloS one13 Aug 2026

PMID42594122 (opens in a new tab)PMCIDPMC13472364 (opens in a new tab)DOI10.1371/journal.pone.0345032 (opens in a new tab)PepBankPUB-42594122
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

BackgroundModest body weight reduction can greatly improve many health-related outcomes. In the SURMOUNT clinical trial program, once-weekly tirzepatide resulted in substantial body weight reductions in people with obesity, without and with type 2 diabetes.ObjectiveThis post-hoc analysis assessed the proportion of participants achieving body weight reduction thresholds (≥5%, ≥10%, ≥15%), systolic blood pressure reduction ≥5 mmHg, and non-high-density lipoprotein cholesterol (non-HDL-C) <130 mg/dL with tirzepatide.MethodsParticipants from SURMOUNT 1-4 randomized to tirzepatide or placebo with valid baseline and ≥1 non-missing post-baseline body weight, systolic blood pressure and non-HDL-C measurements were included in this analysis. The proportion of participants achieving the triple endpoints was assessed at the primary endpoint of each study (Week 72 for SURMOUNT-1, SURMOUNT-2 and SURMOUNT-3 and Week 88 for SURMOUNT-4).ResultsAcross the trials, 32-38% vs 2-8% of tirzepatide-treated vs placebo-treated participants achieved ≥5% body weight reduction, systolic blood pressure reduction ≥5 mmHg, and non-HDL-C <130 mg/dL, 28-37% vs 1-5%, respectively, achieved the triple endpoint with the ≥10% body weight reduction threshold, and 22-34% vs 1-3%, respectively, achieved the triple endpoint with the ≥15% body weight reduction threshold. The between-treatment odds ratios for these proportions across the trials, were statistically significant (all p<0.001).ConclusionIn this post hoc analysis of SURMOUNT, more participants achieved the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL-C <130 mg/dL with tirzepatide vs placebo. Studies evaluating the potential cardiovascular benefits of tirzepatide are ongoing.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people with obesity, 32-38% of tirzepatide-treated participants versus 2-8% of placebo-treated participants achieved body weight reduction of 5% or more, systolic blood pressure reduction of 5 mmHg or more and non-HDL-C below 130 mg/dL.

    In plain wordsIn people with obesity, many more people on tirzepatide than on placebo reached a weight loss, blood pressure and cholesterol goal together.

    Peptide
    Tirzepatide
    Outcome
    IncreaseTriple endpoint with body weight reduction of 5% or more
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 72 or 88 weeksAs given in this study (human).

    Measurements

    Proportion achieving triple endpoint
    32 to 38%
    tirzepatide, weight reduction >=5%
    Proportion achieving triple endpoint
    2 to 8%
    placebo, weight reduction >=5%

    Source sentences

    Summary
    Across the trials, 32-38% vs 2-8% of tirzepatide-treated vs placebo-treated participants achieved ≥5% body weight reduction, systolic blood pressure reduction ≥5 mmHg, and non-HDL-C <130 mg/dL
    2 context sentences
    Summary · context
    The between-treatment odds ratios for these proportions across the trials, were statistically significant (all p<0.001).
    Summary · context
    Participants from SURMOUNT 1-4 randomized to tirzepatide or placebo with valid baseline and ≥1 non-missing post-baseline body weight, systolic blood pressure and non-HDL-C measurements were included in this analysis.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In people with obesity, 28-37% of tirzepatide-treated participants versus 1-5% of placebo-treated participants achieved the triple endpoint with body weight reduction of 10% or more.

    In plain wordsIn people with obesity, many more people on tirzepatide than on placebo reached a 10% weight loss, blood pressure and cholesterol goal together.

    Peptide
    Tirzepatide
    Outcome
    IncreaseTriple endpoint with body weight reduction of 10% or more
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 72 or 88 weeksAs given in this study (human).

    Measurements

    Proportion achieving triple endpoint
    28 to 37%
    tirzepatide, weight reduction >=10%
    Proportion achieving triple endpoint
    1 to 5%
    placebo, weight reduction >=10%

    Source sentences

    Summary
    28-37% vs 1-5%, respectively, achieved the triple endpoint with the ≥10% body weight reduction threshold
    2 context sentences
    Summary · context
    The between-treatment odds ratios for these proportions across the trials, were statistically significant (all p<0.001).
    Summary · context
    Participants from SURMOUNT 1-4 randomized to tirzepatide or placebo with valid baseline and ≥1 non-missing post-baseline body weight, systolic blood pressure and non-HDL-C measurements were included in this analysis.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In people with obesity, 22-34% of tirzepatide-treated participants versus 1-3% of placebo-treated participants achieved the triple endpoint with body weight reduction of 15% or more.

    In plain wordsIn people with obesity, many more people on tirzepatide than on placebo reached a 15% weight loss, blood pressure and cholesterol goal together.

    Peptide
    Tirzepatide
    Outcome
    IncreaseTriple endpoint with body weight reduction of 15% or more
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 72 or 88 weeksAs given in this study (human).

    Measurements

    Proportion achieving triple endpoint
    22 to 34%
    tirzepatide, weight reduction >=15%
    Proportion achieving triple endpoint
    1 to 3%
    placebo, weight reduction >=15%

    Source sentences

    Summary
    22-34% vs 1-3%, respectively, achieved the triple endpoint with the ≥15% body weight reduction threshold.
    2 context sentences
    Summary · context
    The between-treatment odds ratios for these proportions across the trials, were statistically significant (all p<0.001).
    Summary · context
    Participants from SURMOUNT 1-4 randomized to tirzepatide or placebo with valid baseline and ≥1 non-missing post-baseline body weight, systolic blood pressure and non-HDL-C measurements were included in this analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.